...
首页> 外文期刊>BMC Medical Genetics >LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
【24h】

LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies

机译:波兰扩张型心肌病患者的LMNA突变:患病率,临床特征和体外研究

获取原文

摘要

Background LMNA mutations are most frequently involved in the pathogenesis of dilated cardiomyopathy with conduction disease. The goal of this study was to identify LMNA mutations, estimate their frequency among Polish dilated cardiomyopathy patients and characterize their effect both in vivo and in vitro . Methods Between January, 2008 and June, 2012 two patient populations were screened for the presence of LMNA mutations by direct sequencing: 66 dilated cardiomyopathy patients including 27 heart transplant recipients and 39 dilated cardiomyopathy patients with heart failure referred for heart transplantation evaluation, and 44 consecutive dilated cardiomyopathy patients, referred for a family evaluation and mutation screening. Results We detected nine non-synonymous mutations including three novel mutations: p.Ser431*, p.Val256Gly and p.Gly400Argfs*11 deletion. There were 25 carriers altogether in nine families. The carriers were mostly characterized by dilated cardiomyopathy and heart failure with conduction system disease and/or complex ventricular arrhythmia, although five were asymptomatic. Among the LMNA mutation carriers, six underwent heart transplantation, fourteen ICD implantation and eight had pacemaker. In addition, we obtained ultrastructural images of cardiomyocytes from the patient carrying p.Thr510Tyrfs*42. Furthermore, because the novel p.Val256Gly mutation was found in a sporadic case, we verified its pathogenicity by expressing the mutation in a cellular model. Conclusions In conclusion, in the two referral centre populations, the screening revealed five mutations among 66 heart transplant recipients or patients referred for heart transplantation (7.6%) and four mutations among 44 consecutive dilated cardiomyopathy patients referred for familial evaluation (9.1%). Dilated cardiomyopathy patients with LMNA mutations have poor prognosis, however considerable clinical variability is present among family members.
机译:背景LMNA突变最常见于扩张型心肌病伴传导疾病的发病机理。这项研究的目的是鉴定LMNA突变,估计其在波兰扩张型心肌病患者中的发生频率,并表征其体内和体外作用。方法在2008年1月至2012年6月之间,通过直接测序筛选了两个患者群体中是否存在LMNA突变:66例扩张型心肌病患者,包括27例心脏移植受者和39例扩张型心肌病患者,因心脏衰竭而接受心脏移植评估,并连续44例扩张型心肌病患者,需进行家庭评估和突变筛查。结果我们检测到9个非同义突变,包括3个新突变:p.Ser431 *,p.Val256Gly和p.Gly400Argfs * 11缺失。在9个家庭中,总共有25家航空公司。携带者的主要特征是扩张型心肌病和伴有传导系统疾病和/或复杂性室性心律失常的心力衰竭,尽管其中五例无症状。在LMNA突变携带者中,六例接受了心脏移植,十四例进行了ICD植入,八例进行了起搏。此外,我们从携带p.Thr510Tyrfs * 42的患者那里获得了心肌细胞的超微结构图像。此外,由于在散发病例中发现了新的p.Val256Gly突变,我们通过在细胞模型中表达突变来验证其致病性。结论总之,在两个转诊中心人群中,筛查发现66例心脏移植受者或被推荐进行心脏移植的患者中有5个突变(7.6%),以及44例接受家族评估的连续扩张型心肌病患者中的4个突变(9.1%)。 LMNA突变的扩张型心肌病患者预后较差,但是家庭成员之间存在相当大的临床变异性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号